New treatments, research, clinical trials and treatment for macular degeneration
MacuCLEAR’s lead proprietary compound MC1101 is being developed to treat the dry form of AMD. Challenging conventional wisdom, this novel compound is delivered in eye drop form. Diabetic retinopathy and other retinal diseases will also be investigated with MacuCLEAR's portfolio of drug candidates.
While novel in this ophthalmic application, the active ingredient of MC1101 has been previously approved by the FDA as an oral antihypertensive drug. Its safety and toxicity profile is well characterized. MC1101 has been granted 505 (b) 2 status and has formal Fast Track designation by the FDA.
MacuCLEAR's Technology Objective is to prevent the progression of Dry AMD to Wet AMD by:
- Restoring choroidal blood flow
- Preventing the rupture of the Bruch’s Membrane
- Treating aging effects of inflammation and oxidative stress